1. Home
  2. MDIA vs OKYO Comparison

MDIA vs OKYO Comparison

Compare MDIA & OKYO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Mediaco Holding Inc.

MDIA

Mediaco Holding Inc.

SELL

Current Price

$0.96

Market Cap

90.7M

ML Signal

SELL

Logo OKYO Pharma Limited

OKYO

OKYO Pharma Limited

SELL

Current Price

$1.18

Market Cap

78.2M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
MDIA
OKYO
Founded
2019
2007
Country
United States
United Kingdom
Employees
N/A
N/A
Industry
Broadcasting
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
90.7M
78.2M
IPO Year
2019
2021

Fundamental Metrics

Financial Performance
Metric
MDIA
OKYO
Price
$0.96
$1.18
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
★ $8.33
AVG Volume (30 Days)
9.1K
★ 282.3K
Earning Date
11-16-2026
07-20-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
★ $133,336,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 39.52
N/A
52 Week Low
$0.54
$1.00
52 Week High
$1.64
$3.20

Technical Indicators

Market Signals
Indicator
MDIA
OKYO
Relative Strength Index (RSI) N/A N/A
Support Level N/A N/A
Resistance Level N/A N/A
Average True Range (ATR) 0.00 0.00
MACD 0.00 0.00
Stochastic Oscillator 0.00 0.00

Price Performance

Historical Comparison
MDIA
OKYO

About MDIA Mediaco Holding Inc.

MediaCo Holding Inc is a radio broadcasting media company operating in radio and digital advertising, premium programming, and events. It has two radio stations, WQHT-FM and WBLS-FM, which serve the New York City metropolitan area. The company generates revenue from radio and outdoor advertising sales, events including sponsorships and ticket sales, licensing, and syndication. The company has two business segments: the Audio segment and the Video segment.

About OKYO OKYO Pharma Limited

OKYO Pharma Ltd is a clinical-stage ophthalmology company focused on developing differentiated therapies for corneal and anterior segment diseases. It is advancing a pipeline designed to improve outcomes for patients suffering from debilitating ocular diseases that impact vision and ocular comfort. The company's main program, urcosimod, is being developed as a potential treatment for neuropathic corneal pain. Additionally, its development pipeline includes an exploratory candidate, OK-201, a non-opioid analgesic drug candidate, as a potential drug to treat acute and chronic ocular pain. The company has only one operating segment: the research and development of biotechnological and pharmaceutical products.

Share on Social Networks: